Affitope AD03

Drug Profile

Affitope AD03

Alternative Names: AD 03; Affitope-AD03; Alzheimer AD03; MimoVax

Latest Information Update: 05 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AFFiRiS
  • Class Alzheimer vaccines
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 05 May 2016 Discontinued - Phase-I for Alzheimer's disease in Austria (SC)
  • 31 Dec 2011 AFFiRiS initiates enrolment (by invitation only) in a phase Ib follow-up trial in Alzheimer's disease in Austria (NCT01568086)
  • 01 Nov 2011 AFFiRiS completes a phase I trial in Alzheimer's disease in Austria (NCT01309763)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top